People
The People
Daqo earns a C+ governance grade: the Xu family has real money on the line and the audit committee is genuinely independent, but a three-generation family board, a CEO who chairs his own nomination committee, a $100M buyback announced and not executed while insiders were filing Form 144 sales, and a CFO who owns zero stock weigh on trust.
Governance Grade
Skin-in-the-Game (1-10)
Insiders & Directors Own (%)
Independent Directors
▲ 11 of Total
The People Running This Company
Five people decide what happens at Daqo. Three of them share a surname.
The bench is shallow. CEO Xiang Xu has spent his career inside the family conglomerate Daqo Group; he runs 25 of its subsidiaries in addition to DQ. Founder Guangfu Xu (83) still sits on the board and owns more stock than anyone, but stepped back in August 2023 alongside CEO Longgen Zhang's abrupt "personal reasons" exit — a sequence that triggered a Rosen Law class-action probe.
The most notable hire is Ming Yang (CFO since 2015). His resume — McKinsey clean-tech, JA Solar BD, Coatue, Piper Jaffray — is the strongest external credential on the team and he is the public face of the IR program. The contradiction: he reportedly owns no Daqo shares.
The succession story is dynastic. Xiaoyu Xu, the CEO's 30-year-old daughter, joined May 2023 as IR head, became a director that November, and was promoted to Deputy CEO in October 2024 — eighteen months from analyst seat to operational #2.
What They Get Paid
For a company that generated $4.6B of revenue at peak and still carries a $1.5B market cap, executive cash compensation is unusually thin — almost all of the value transfer happens through stock.
The signature data point is FY2022: as polysilicon prices peaked and net income hit $1.8B, the company recognized $307M of stock-based compensation — the largest single grant in its history, awarded to insiders at the cyclical top. Since then SBC has remained elevated ($142M, $72M, $56M) even as the company swung to losses. Cumulative grants total 117.7M RSUs and options against 67M ADS outstanding.
Cash pay is modest, but the equity machine is large. $307M of SBC granted in the peak year, followed by four years of further dilution while the stock fell more than 70% from its 2021 high — the structure rewards being employed at the top of the cycle, not creating value through it.
Are They Aligned?
The Xu family controls roughly 30% of the company directly through BVI vehicles. That is real skin in the game. The picture gets more complicated when you look at insider behavior since the cycle turned.
Skin-in-the-Game Score (of 10)
Insider trading. As a Cayman-incorporated foreign private issuer, Daqo is exempt from Section 16 / Form 4 filings, so insider trading is only visible through Form 144s (planned sales) and Schedule 13G/A (5%+ holders). Four Form 144s were filed between Sept and Dec 2025. There is no equivalent public record of insider buys.
Buyback execution. In August 2025 the board authorized a $100M repurchase program. Six months later management has executed only ~$1M, citing waiting "for clarity on China's anti-involution policies" and the cost of the prospective industry consolidation platform. In Q3 2025 the IR head explained the stock had run from $23 to $31 — "we wanted to purchase more shares, we were waiting." This is the textbook mistake: buy back when expensive, hold cash when cheap. With the stock back near $22 and a $1.5B market cap, the program is overdue.
Related-party transactions. Material in form but immaterial in amount. The 20-F discloses ~$0.7M of total annual purchases/services with eleven Daqo Group affiliates (Zhenjiang Daqo, Nanjing Daqo Electric, Saide Fire Protection, Jiangsu Changjiang Hotel, etc.). All of these are controlled by the Xu family conglomerate. In dollars, the leakage is rounding error against a $665M revenue base — but it shows the operating environment is enmeshed with a private family group.
The bigger related-party event is historical: in June 2020 the board sold 4.4% of operating subsidiary Xinjiang Daqo to four insiders (Guangfu Xu, Xiang Xu, Dafeng Shi, then-CEO Longgen Zhang) at a pre-money valuation of RMB 4.52B (~$637M) ahead of the STAR Market listing. When Xinjiang Daqo subsequently IPO'd on the STAR board, those insiders captured a substantial multiple on the pre-IPO discount.
The August 2023 leadership transition — founder Guangfu Xu stepping down as chairman, simultaneously with CEO Longgen Zhang's abrupt "personal reasons" exit — drew a Rosen Law securities investigation. No class-action class period was certified, but the simultaneity remains an unresolved governance flag.
Board Quality
On paper the board satisfies NYSE majority-independence: 6 of 11 directors are independent. In practice the room is structurally tilted toward management.
The most consequential governance defect: the Nominating & Governance Committee is chaired by the CEO. The body responsible for selecting the next round of directors — including the independent overseers of his own performance — is led by the man being overseen. NYSE rules don't prohibit this for foreign private issuers, but it is the structural opposite of best practice.
The audit committee is the bright spot. Arthur Wong (chair) spent 26 years at Deloitte ending as a Beijing partner, then served as CFO at four China-listed renewable / hospitality companies. He is the SEC-defined "audit committee financial expert" and is unambiguously independent. Rongling Chen brings ASML / Applied Materials semiconductor expertise. Minsong Liang (PhD Michigan, JD NYU) is an ex-CSRC adviser. The audit committee held four formal meetings in 2025 plus two written resolutions — the highest cadence on the board.
The compensation and nominating committees, by contrast, met by written resolution only once each in 2025. Neither held a formal meeting.
Director tenure and age skew old. Five independent directors are between 61 and 84; three have been on the board since 2009-2011 (16+ year tenure, well past the 10-year mark where independence is typically considered impaired by ISS). Founder Guangfu Xu (83) and independent director Rongling Chen (84) are the same age cohort.
The Verdict
Governance Grade
Skin in the Game
▲ 7 of 10
The strongest positives. The Xu family owns ~30% directly — there is no principal-agent problem at the founder level. The audit committee is fully independent and chaired by a Deloitte CPA, which matters for a Chinese ADR where audit risk is the largest tail. CFO Ming Yang has the strongest individual resume on the team and has held the seat for a decade. Cash compensation is modest in absolute terms.
The real concerns. Three structural defects matter most. First, the CEO chairs the Nominating & Governance Committee — the body that picks the independent watchdogs — making "independence" partly elective. Second, the Compensation Committee is chaired by a non-independent insider, and the Comp / Nom committees met only by written resolution in 2025, with no formal meetings. Third, succession is dynastic: a 30-year-old daughter promoted from analyst to Deputy CEO in 18 months, with zero disclosed share ownership. Layered on top: a $100M buyback authorized but not executed while the stock sat near multi-year lows and Form 144 sale filings clustered in late 2025; SBC of $307M handed out at the cyclical peak in 2022; and a Cayman / FPI structure that exempts the company from Section 16 / Form 4 transparency.
What would upgrade the grade to B / B+.
Three things together would move the grade. (a) An independent director — not the CEO — taking the chair of the Nominating & Governance Committee. (b) Visible execution of the $100M buyback at current prices, demonstrating the board acts on its own capital allocation signal. (c) A succession plan that names a non-Xu candidate or, at minimum, requires the Deputy CEO to build a meaningful share stake before further promotion.
What would downgrade to D. Any of: (a) a related-party transaction larger than today's rounding-error scale, especially involving Xinjiang Daqo subsidiary stock; (b) auditor turnover or a material weakness in internal controls; (c) a regulatory action by the SEC or PCAOB; (d) acceleration of insider Form 144 selling without offsetting buybacks.